Vaxxinity’s Phase III Covid-19 booster trial meets endpoints

Vaxxinity has reported that its Phase III clinical trial of Covid-19 the vaccine UB-612 as a booster met the primary and crucial secondary immunogenicity endpoints.

The trial enrolled a total of 944 subjects aged 16 years and above at seven centres in the US, Panama, and the Philippines.